| Wissenschaftl. Titel | A prospective, randomised, controlled, open label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatinreceptor positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) |
| Erkrankung |
Drüsen/Hormone/Stoffwechsel:
Neuroendokrine Tumoren
|
| Molekularer Marker |
SSTR |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 20.05.2019 Student Studienregister
geändert 12.04.2022 Nicole Wamser